Actively Recruiting
Phase 1 Study Comparing Intravenous and Subcutaneous Risankizumab in Healthy Adults
Led by AbbVie · Updated on 2026-07-01
60
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This study evaluates how the drug risankizumab moves through the body when given by two different methods intravenous IV infusion and subcutaneous SC injection. It is a Phase 1 trial involving healthy adult volunteers aged 18 to 65 years. The purpose is to compare the processing of risankizumab in the body depending on the administration route. Participants will be randomly assigned to receive either Dose A of risankizumab through intravenous infusion or Dose B via subcutaneous injection. Both groups receive the study drug as a single dose, and the trial monitors how the drug is absorbed and processed over time. During the study, participants will be monitored for adverse events and have blood samples taken to measure drug concentration levels, including maximum serum concentration Cmax, time to reach this maximum Tmax, and the area under the concentration-time curve AUC. These measurements will be collected for up to approximately 155 days to assess the drugs behavior in the body. The study includes physical exams, vital signs, lab tests, and ECGs to ensure participant health throughout the trial.
CONDITIONS
Brief Title
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
